Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Design Therapeutics Inc shares valued at $891,600 were purchased by Logos Global Master Fund LP on Nov 18 ’25. At $7.43 per share, Logos Global Master Fund LP acquired 120,000 shares.
Also, Logos Global Master Fund LP purchased 620,000 shares, netting a total of over 4,377,200 in proceeds.
Before that, Logos Global Master Fund LP had added 415,000 shares to its account. In a trade valued at $2,851,050, the Director bought Design Therapeutics Inc shares for $6.87 each.
As published in a research note from RBC Capital Mkts on November 20, 2025, Design Therapeutics Inc [DSGN] has been rated up from a Sector perform to an Outperform and the price target has been revised to $13. Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in early May. As of November 14, 2023, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for DSGN. Earlier on August 15, 2023, Wedbush downgraded its rating. Their new recommendation was “a Neutral” for DSGN stock which previously was a “an Outperform”.
Analyzing DSGN Stock Performance
On last trading session, Design Therapeutics Inc [NASDAQ: DSGN] rose 7.22% to $7.87. The stock’s lowest price that day was $7.81, but it reached a high of $8.8 in the same session. During the last five days, there has been a surge of approximately 11.47%. Over the course of the year, Design Therapeutics Inc shares have jumped approximately 36.63%. Shares of the company reached a 52-week high of $8.80 on 11/20/25 and a 52-week low of $2.60 on 04/11/25.
Support And Resistance Levels for Design Therapeutics Inc (DSGN)
According to the 24-hour chart, there is a support level at 7.52, which, if violated, would cause prices to drop to 7.17. In the upper region, resistance lies at 8.51. The next price resistance is at 9.15. RSI (Relative Strength Index) is 61.78 on the 14-day chart, showing neutral technical sentiment.
Is Design Therapeutics Inc subject to short interest?
Stocks of Design Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -1.7 million shares to 1.85 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 3.55 million shares. A decline of -92.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.64 of the overall float, the days-to-cover ratio (short ratio) decline to 9.64.
Which companies own the most shares of Design Therapeutics Inc (DSGN)?
In terms of Design Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 36.24% from the previous closing price of $7.34. Analysts anticipate Design Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 7. In spite of this, 2 analysts ranked Design Therapeutics Inc stock as Buy at the end of 2025. On August 15, 2023, SVB Securities assigned a price target of “a Market perform” to the stock and downgraded coverage with a $6.
